Groundbreaking HIV vaccine enters late-stage testing in US and Europe

A potential vaccine is being welcomed by HIV prevention advocates with ‘cautious optimism’

A vaccine targeting multiple strains of HIV is going into late-stage testing in the US and Europe later this year, but HIV experts have expressed ‘optimistic caution.’

Pharmaceutical giant Johnson & Johnson (J&J) is gearing up to test a new type of vaccine against HIV, according to Bloomberg.

Although, some HIV prevention advocates have highlighted the continued importance of current treatments – PrEP and condoms – in the road to ending HIV.

What does the trial involve?

The Mosaico study will see more than 3,800 men who have sex with men given a series of injections that the company hope will stop people from acquiring HIV.

Participants will receive six shots over four sessions, Anthony Fauci, the director of the US National Institute of Allergy and Infectious Diseases, told Bloomberg.

Moreover, he added that two thirds of animals given the vaccine developed immunity to HIV.

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

Start typing and press enter to search